Industry landscapes
The companies, capital and talent shaping life sciences in Switzerland. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
79 of 1,129 tracked companies have open roles.
389 of 1,129 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 785 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 16.6% of disclosed capital, while 65.5% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $517.95M | 55 | 40 |
| 2017 | $690.24M | 65 | 54 |
| 2018 | $477.48M | 61 | 61 |
| 2019 | $789.65M | 59 | 77 |
| 2020 | $985.62M | 52 | 79 |
| 2021 | $2.3B | 44 | 73 |
| 2022 | $874.04M | 38 | 80 |
| 2023 | $974.27M | 32 | 48 |
| 2024 | $1.19B | 22 | 54 |
| 2025 | $1.7B | 9 | 48 |
Share of all disclosed company funding.
940 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Orbimed and Novo Holdings and others.
Backed by Protocol Labs and IAG Capital Partners and others.
Backed by .
Backed by Lotus One Investment and VP Venture Partners and others.
Backed by Eir Partners.
Backed by Forty51 Ventures.
Backed by .
Backed by Mission BioCapital.
Backed by AstraZeneca and Auven Therapeutics and others.
Backed by Novo Holdings and Orbimed and others.
Backed by Orbimed and Novo Holdings and others.
Backed by Andera Partners and NovaQuest Capital Management and others.
Backed by Orbimed and Novo Holdings and others.
Backed by Revival Healthcare Capital.
Backed by Revival Healthcare Capital.
Backed by Novo Holdings and Catalio Capital Management and others.
Participating investors were not recorded in this snapshot.
Backed by Forbion and Novartis Venture Fund and others.
No reviewed exact national-ID connector maps Switzerland company identities to the configured global filings table.; No reviewed exact national-ID connector maps Switzerland company identities to the configured global filings table.
How the Switzerland companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
5 of the 1,129 companies on this page carry a measured traffic record (0.4%); these are the largest of those, by monthly visits. The median among them is 102,658 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Phonakphonak.com | 1,030,142 | 52 | 86.5% |
| ExPASyexpasy.org | 369,914 | 51 | 12.7% |
| Ascensiaascensia.com | 102,658 | 33 | 93.1% |
| Unilabsunilabs.com | 92,384 | 36 | 59% |
| Nobel Biocarenobelbiocare.com | 78,674 | 44 | 5.6% |
Visits and authority are third-party web estimates, not company-reported figures.
32 of these companies (2.8%) publish at least one Android app — 122 apps in all, carrying 12.7M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| myPhonakPhonak | 4.2M | 4.5 | Medical |
| Cropwise Grower - Kisan AppSyngenta | 3.8M | 4.8 | Productivity |
| Medela Family - Breast FeedingMedela | 906.1K | 4.3 | Medical |
| CONTOUR DIABETES app (US)Ascensia | 443.5K | 3.3 | Medical |
| Bernafon AppBernafon | 348.6K | 3.3 | Medical |
| Cropwise Grower IndonesiaSyngenta | 294K | — | Productivity |
| CONTOUR DIABETES appAscensia | 249K | — | Medical |
| CONTOUR DIABETES app (DE)Ascensia | 206.5K | — | Medical |
| CONTOUR DIABETES app (CA)Ascensia | 186.1K | — | Medical |
| mylife™ Appmylife Diabetescare | 167.2K | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Wearable Technology | 15 | 6M | myPhonak 4.2M | |
| Consumer Electronics E-Commerce | 10 | 5.7M | Medela Family - Breast Feeding 906.1K | |
| Ent Disorders | 6 | 4.7M | Bernafon App 348.6K | |
| Genomics | 11 | 4.3M | Cropwise Grower - Kisan App 3.8M | |
| Audio Tech | 5 | 4.3M | myRogerMic 63.3K | |
| Diabetes | 64 | 2.5M | CONTOUR DIABETES app (US) 443.5K | |
| Disease Self Management | 10 | 1.3M | mylife™ App 167.2K | |
| Women Health | 6 | 1.1M | Ava Fertility 112.9K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 43 of 122 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
59 companies hiring · $12.29B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Boehringer Ingelheim forged a similar agreement with CDR-Life in November 2025, handing over up to $570m for the global rights to the latter’s trispecific autoimmune therapy, CDR111.
The funding round is Rivia’s first since 2024, when it raised €3 million ($3.5 million) from backers Speedinvest, Amino Collective, and Nina Capital.
Sunshine SwissCo GmbH, an affiliate of the EQT VIII fund (“EQT VIII”), together with other selling shareholders, is pleased to announce the completion of the placement of c. 34.0 million shares (the “Shares”) in Galderma Group AG (SIX: GALD) (“Galderma”) for aggregate gross proceeds of c. CHF 4.9 billion via an accelerated bookbuilding process (the “Placement”).
Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of its seed financing round with an additional CHF 3 million. This additional funding brings the total seed round to CHF 6.9 million ($8.9 million).
Pregnolia (2016, ZH) developed a medical device for the improvement of pregnancy care, which allows health care providers to measure the stiffness of the cervix for a more complete characterization of cervical status. The company has been selected as recipient of blended finance from EIC.
Kellerhals Carrard advised Haelixa, as the Swiss deep-tech company has closed a pre-series A financing round. Verve Ventures and Zürcher Kantonalbank led the funding, with participation from impact-focused investor 212.
New Delhi: Alkem Laboratories Limited announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has made a binding offer dated February 13, 2026, to acquire between 51% and 55% of the total issued equity share capital of Switzerland-based Occlutech Holding AG from certain existing shareholders.
Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors.
Syngenta was reported to be planning for Hong Kong IPO after cancelling Shanghai IPO application in 2024 March to raise $9.1 billion with $60 billion enterprise value.
Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Facility") entered into on 17 March 2025 between the Company and GEM Global Yield LLC SCS ("GEM"). Under the terms of the Facility, GEM has agreed, subject to certain conditions, to commit an amount of up to EUR 20 million in cash...
Top 10 categories among 677 recorded events in the 24-month window.
17 companies with recorded IPO activity
IPO · SIX Swiss Exchange5 reports
IPO · Hong Kong5 reports
IPO · SIX Swiss Exchange10 reports
IPO2 reports
Follow-on Offering · NASDAQ8 reports
IPO · Swiss Stock Exchange3 reports
IPO1 reports
IPO · Swiss Stock Exchange2 reports
32 tracked people moves
Resignation Previously Head of the Group
Appointment Head of the Group
Appointment Chief Executive Officer
Appointment Chief Executive Officer
Departure Previously Chief Executive Officer
Appointment Board Member
Appointment President and CEO
Appointment Chief Financial Officer
Products, platforms and features in the recorded window
Hybrid air‑freight container
Platform
Digital Agriculture
13 recorded customer wins
Customer: OSR Holdings
Customer: Nxera Pharma UK Ltd.Pharmaceutical
Customer: BCM Europe AGPharmaceutical
Customer: senseonicsDiabetes Technology
Customer: Ikris PharmaBiopharma
Customer: pfizer
5 companies with reported reductions
52 rolescash runway extension
80 rolescost cuts
40 rolesstrategic review
28 rolescost reduction
Scale not stated rolescost reduction
14 recorded events
510(k) clearance grantedU.S. Food and Drug Administration (FDA)
approved for DMD treatmentHealth Canada
approved for Phase I clinical studiesFDA
approved for treating severe chronic hand eczema refractory to topical corticosteroids
7 tracked suits
exposure to paraquat pesticide causing Parkinson\'s diseaseCivil · Ongoing
misleading statements about drug trial results leading to investor lossesSecurities Fraud · Filed
Reported company results in the recorded window.
Median across 46 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| chemchina→Syngenta ↗ | Pending | 2026-05-18 | Not stated in snapshot |
| boehringer ingelheim→CDR-Life ↗ | Announced | 2026-03-24 | $570.0M |
| Alkem Medtech→Occlutech ↗ | Announced | 2026-02-16 | Not stated in snapshot |
| bruker→TOFWERK ↗ | Completed | 2026-01-16 | Not stated in snapshot |
| Matrix One→dokspot ↗ | Completed | 2026-01-07 | Not stated in snapshot |
| L’Oréal→Galderma ↗ | Announced | 2026-01-06 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
221 postings in the preceding 12 months. The full 833-posting snapshot covers 44 employers.
0 tracked postings mention remote work.
417 postings specify a level.
Top skills across 833 tracked postings in the available jobs snapshot.
| Company | Open roles |
|---|---|
| Galderma ↗ | 13 |
| Sentec ↗ | 8 |
| Straumann Group ↗ | 8 |
| Unilabs ↗ | 7 |
| Hamilton Medical ↗ | 7 |
| Ypsomed ↗ | 6 |
| Nanolive ↗ | 5 |
| Sanoptis ↗ | 5 |
| Company | Employees |
|---|---|
| Octapharma ↗ | 2,697 |
| Tecan ↗ | 2,318 |
| Medartis ↗ | 858 |
| Phonak ↗ | 772 |
| Inpeco ↗ | 544 |
| CRISPR Therapeutics ↗ | 458 |
| SHL Group ↗ | 444 |
| AliveDx ↗ | 432 |
850 founders and chief executives across 560 companies.
Co-Founder ADC Therapeutics, ex-Founder Cibus, Celtic Pharma Management, Royalty Pharma, PaineWebber. University of Cambridge 1973
Cequr, ex-Stryker, ex-Microchips, Kellogg School of Management, Chicago, 2012
Ex-Zimmer Biomet, Stryker. Miami University BA 1995, Cleveland State University JD 1998
Ex-Ridgeline Therapeutics, Black Diamond Therapeutics, Roche. University of Naples Federico II MD, TU Dresden PhD
Co-CEO-MindMaze · Ex-Bayer Pharmaceuticals, Voluntis, Sanofi · Sciences Po 1996, Paris Dauphine University - PSL 1998, HEC Paris 1998
Ex-Bobst. Stanford University BBA 2005, University of Friborg BA 2007
Co-Founder Flamboyant, Founder HIM, ex- CFO ARTEMIS Augenkliniken und med. Versorgungszentren, CFO AMEOS Group. University of Mannheim 2000…
CEO Syngenta Group, ex-CEO Nalco, Univar, DuPont. University of Delaware BE 1981
Xeltis, ex-The Medicines, ex-Profibrix, Maastricht University, 2004
Co-Founder Synple Chem. Trinity University BA 1996, Caltech PhD 1998
Noema Pharma, ex-Retrotope, ex-Medday Pharmaceuticals, Paris Descartes
Numab Therapeutics, ex-Numab, ex-Esbatech An Alcon Biomedical Research Unit, Biocenter, Basel, 2004
83 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
279,795 articles in the measured 12-month window.
Life Sciences coverage across Switzerland · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 23,436 |
| 2021Q3 | 24,059 |
| 2021Q4 | 19,616 |
| 2022Q1 | 24,159 |
| 2022Q2 | 23,513 |
| 2022Q3 | 21,860 |
| 2022Q4 | 30,031 |
| 2023Q1 | 28,856 |
| 2023Q2 | 28,631 |
| 2023Q3 | 23,753 |
| 2023Q4 | 21,625 |
| 2024Q1 | 30,706 |
| 2024Q2 | 31,180 |
| 2024Q3 | 29,303 |
| 2024Q4 | 26,562 |
| 2025Q1 | 45,699 |
| 2025Q2 | 27,121 |
| 2025Q3 | 199,636 |
| 2025Q4 | 20,831 |
| 2026Q1 | 32,433 |
Article volume measures coverage, not market sales.
1,038 recorded company events across 122 companies; percentages use that event total.
Life Sciences coverage across Switzerland · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Switzerland
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 2,199 | 707 | 211% |
| free trade deals | 1,234 | 372 | 232% |
| trade dispute mechanisms | 1,122 | 254 | 342% |
| bilateral trade | 1,019 | 239 | 326% |
| diplomatic strategies | 539 | 321 | 68% |
| multilateral diplomacy | 536 | 242 | 121% |
| preferential tariff | 515 | 197 | 161% |
| trade barrier reduction | 463 | 146 | 217% |
| women\'s champions league | 463 | 172 | 169% |
| tariff rate quota | 421 | 157 | 168% |
| europa league | 160 | 899 | -82% |
| quarterfinals | 231 | 676 | -66% |
| final match | 139 | 639 | -78% |
| final match recaps | 253 | 546 | -54% |
| multilateral accords | 150 | 263 | -43% |
Life Sciences coverage across Switzerland
tariff negotiations, free trade deals, monetary easing
40.4% critical · 31.2% positivecurrency intervention policies, inflation reports fx, trade deficits fx
38.0% critical · 44.3% positivegdp growth forex, inflation reports fx, currency intervention policies
31.7% critical · 47.7% positiveLife Sciences coverage across Switzerland. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Researchers discuss challenges in using microbes and plants for biofuel, biorefinery, and nutrient recycling.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Papers highlight microbial hazards, processing impacts, and health implications of modern food products.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Studies examine mRNA, gene regulation, and cell‑culture methods for disease treatment and veterinary biosimilars.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Research focuses on fertiliser strategies, nutrient‑use efficiency, and germplasm improvement for secure food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Works address host‑pathogen interactions, fungicide use, and integrated pest‑management tactics.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Analyses cover resistance emergence in humans, livestock, and the environment and its broader impacts.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
A diverse set of papers explores unrelated biochemical, legal, and methodological subjects.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Investigations caution about in‑vitro and in‑vivo models for assessing microplastic and drug‑induced stress.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Authors warn of complexities in breeding decisions and alternative protein sources for poultry.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Papers advise careful evaluation of bioactive feed compounds and plant‑protein substitution effects.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Research highlights potential hazards from caffeine, insect pigments, and other emerging food contaminants.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Studies caution about interpreting gene‑expression changes linked to DNA repair and cancer diagnostics.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Works stress the intertwined spread of antibiotic, biocide, and metal resistance in food‑borne microbes.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Authors discuss modeling pesticide dosing and the limits of fungal endophytes for pest management.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Opportunities arise from novel antibodies, fluorescence methods, and flow cytometry for in‑vivo studies.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Research points to therapeutic potential of gene knockdown, apoptosis control, and cell‑growth regulation.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Papers explore health‑promoting ingredients, bioactive compounds, and sustainable protein sources.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Studies reveal prospects for DNA‑methylation editing and sensitive miRNA detection platforms.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Research highlights plant‑derived antimicrobials and microbial metabolites improving animal health.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Works focus on germplasm analysis, QTL mapping, and selection strategies to boost wheat productivity.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Papers present microbial fermentation and by‑product valorisation as routes to greener agriculture.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.5% |
| Promising | 30.4% | 37.3% |
| Breakthrough | 14.1% | 26.0% |
| Problem-identifying | 8.3% | 9.7% |
| Cautionary | 3.5% | 4.7% |
| Comparative | 2.4% | 3.9% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
29.3% across the displayed hubs
15 companies hiring · $2.0B disclosed funding
Explore companies in Zurich ↗
21.6% across the displayed hubs
12 companies hiring · $3.9B disclosed funding
Explore companies in Basel ↗
16.2% across the displayed hubs
8 companies hiring · $1.2B disclosed funding
Explore companies in Lausanne ↗
11.8% across the displayed hubs
5 companies hiring · $851.9M disclosed funding
Explore companies in Geneva ↗
7.9% across the displayed hubs
1 companies hiring · $919.4M disclosed funding
Explore companies in Schlieren ↗
5.2% across the displayed hubs
4 companies hiring · $608.2M disclosed funding
Explore companies in Zug ↗
4.3% across the displayed hubs
2 companies hiring · $1.3B disclosed funding
Explore companies in Epalinges ↗
3.8% across the displayed hubs
2 companies hiring · $54.9M disclosed funding
Explore companies in Bern ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗